We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » U.S. FDA’s Tropical Disease Priority Review Voucher Fee Set at $2.7 Million
U.S. FDA’s Tropical Disease Priority Review Voucher Fee Set at $2.7 Million
Drugmakers submitting an NDA or BLA with a tropical disease priority review voucher in the U.S. will now pay a $2.7 million fee — a $165,000 increase over fiscal year 2015, which ended Sept. 30.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor